Syncor to distribute PerImmune MoAb

Radiopharmacy firm Syncor International of Woodland Hills, CA, has signed an agreement for worldwide distribution of monoclonal antibody-based imaging and therapy agents under development by PerImmune of Rockville, MD. The deal includes HumaSPECT/CR, a human monoclonal antibody for the diagnosis and staging of colorectal cancer that PerImmune is developing. Syncor also announced that it has completed its acquisition of the iodine-123 business of Golden Pharmaceuticals of Golden, CO (SCAN 2/19/97).